Skip to main content
Premium Trial:

Request an Annual Quote

Don't Forget the Caveat

At in the Pipeline, Derek Lowe applies a Wired article on David Li's formula that allowed Wall Street to make vast amount of money (while overlooking the formula's limitations, which ultimately is crashing down around their ears) to drug discovery and development. Lowe says many of the examples in the Wired piece can be extended to that industry:

"What are the risks of each compound in Company X's pipeline failing? If a compound with a similar mechanism wipes out over at Company Y, how have the odds now changed? What about patent risks - if a Supreme Court decision makes everyone rethink issues of infringement or obviousness, how correlated are the patent-busting exposure around the industry? And so on…" he writes.

Lowe adds that the difference is that pharma hasn’t quite convinced itself that everything's all figured out nor has issued securities.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.